Abstract
Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bax (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Bcl-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was a reciprocal downregulation of the endogenously expressed Bcl-XL in the Bcl-2 overexpressing clones. Downregulation of Bcl-XL to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Bcl-2 and Bcl-XL have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Bcl-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- FBA:
-
filter binding assay
- NMF:
-
N-methylformamide
- TGCT:
-
testicular germ cell tumours
- TCC:
-
transitional cell carcinomas
References
Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein A, Lozano G, Sarkiss M and McDonnell TJ. . 1997 Oncogene 15: 2767–2772.
Bertrand R, Sarang M, Jenkin J, Kerrigan D and Pommier Y. . 1991 Cancer Res. 51: 6280–6285.
Boersma AWM, Nooter K, Burger H, Kortland CJ and Stoter G. . 1997 Cytometry 27: 275–282.
Burger H, Nooter K, Boersma AWM, Kortland CJ and Stoter G. . 1997 Int. J. Cancer 73: 592–599.
Chao DT, Linette GP, Boise LH, White LS, Thompson CB and Korsmeyer SJ. . 1995 J. Exp. Med. 182: 821–828.
Cheng EHY, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwick JM. . 1997 Science 278: 1966–1968.
Chresta CM, Masters JRW and Hickman JA. . 1996 Cancer Res. 56: 1834–1841.
Cosulich SC, Green S and Clarke PR. . 1996 Curr. Biol. 6: 997–1005.
Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K, Zangemeister-Wittke U, Akbar AN and Simon HU. . 1998 Blood 92: 778–783.
Dive C and Hickman JH. . 1991 Br. J. Cancer 64: 192–196.
Einhorn LH. . 1990 J. Clin. Oncol. 8: 1777–1781.
Farrow SN and Brown R. . 1996 Curr. Opin. Gen. Dev. 6: 45–49.
Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C and Hickman JA. . 1993 Cancer Res 53: 3321–3326.
Gottschalk AR, Boise LH, Thompson CB and Quintans J. . 1994 Proc. Natl. Acad. Sci. USA 91: 7350–7354.
Haldar S, Chintapalli J and Croce CM. . 1996 Cancer Res. 56: 1253–1255.
Haldar S, Jena N and Croce CM. . 1995 Proc. Natl. Acad. Sci. USA 92: 4507–4511.
Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA and Wyche JH. . 1996 Cancer Res. 56: 1621–1628.
Hashimoto H, Chatterjee S and Berger NA. . 1995 Cancer Res. 55: 4029–4035.
Hockenbery DM, Zutter M, Hickey W, Nahm M and Korsmeyer SJ. . 1991 Proc. Natl. Acad. Sci. USA 88: 6971–6965.
Hsu YT, Wolter KG and Youle RJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 3668–3672.
Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y and Cossman J. . 1993 Cancer Res. 53: 4251–4256.
Kluck RM, BossyWetzel E, Green DR and Newmeyer DD. . 1997 Science 275: 1132–1136.
Knudson CM and Korsmeyer SJ. . 1997 Nature Genetics 16: 358–363.
Korsmeyer SJ. . 1995 Trends Genet. 11: 101–105.
Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K and Reed JC. . 1995 Am. J. Pathol. 146: 1309–1319.
Krajewski S, Krajewska M, Shabaik A, Wang H, Irie S, Fong L and Reed JC. . 1994 Cancer Res. 54: 5501–5507.
Kroemer G. . 1997 Nature Med. 3: 614–620.
Kroemer G, Zamzami N and Susin SA. . 1997 Immunol Today 18: 44–51.
Lock RB and Stribinskiene L. . 1996 Cancer Res. 56: 4006–4012.
Lu QL, Poulsom R, Wong L and Hanby AM. . 1993 J. Pathol. 169: 431–437.
Naumovski L and Cleary ML. . 1996 Mol. Cell. Biol. 16: 3884–3892.
O'Reilly LA, Huang D and Strasser A. . 1996 EMBO J. 15: 6979–6990.
Oltvai ZN and Korsmeyer SJ. . 1994 Cell 79: 189–192.
Oltvai ZN, Milliman CL and Korsmeyer SJ. . 1993 Cell 74: 609–619.
Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW and Vogelstein B. . 1994 Cancer Res. 54: 3714–3717.
Reed JC. . 1994 J. Cell Biol. 124: 1–6.
Reed JC. . 1997 Nature 387: 773–776.
Schwarze MMK and Hawley RG. . 1995 Cancer Res. 55: 2262–2265.
Simonian PL, Grillot D and Nunez G. . 1997a Blood 90: 1208–1216.
Simonian PL, Grillot DAM, Merino R and Nunez G. . 1996 J. Biol. Chem. 271: 22764–22772.
Simonian PL, Grillot DAM and Nunez G. . 1997b Oncogene 15: 1871–1875.
Uhlmann EJ, Subramanian T, Vater CA, Lutz R and Chinnadurai G. . 1998 J. Biol. Chem. 273: 17926–17932.
Walker A, Taylor ST, Hickman JA and Dive C. . 1997 Cancer Res. 57: 1939–1945.
Wang HG, Rapp UR and Reed JC. . 1996 Cell 87: 629–638.
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ. . 1997 J. Cell Biol. 139: 1–12.
Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer J. . 1995 Cell 80: 285–291.
Yang J, Liu XS, Bhalla K, Kim CN, Ibrado AM, Cai JY, Peng TI, Jones DP and Wang XD. . 1997 Science 275: 1129–1132.
Yin DX and Schimke RT. . 1995 Cancer Res. 55: 4922–4928.
Zhu W, Cowie A, Wasfy GW, Penn LZ, Leber B and Andrews DW. . 1996 EMBO J. 15: 4130–4141.
Zou H, Henzel WJ, Liu XS, Lutschg A and Wang XD. . 1997 Cell 90: 405–413.
Acknowledgements
We thank Dr Sabina Cosulich for providing the pcDNA3-Bcl-2 plasmid and Dr Uwe Zangemeister-Wittke, Department of Oncology, University Hospital Zurich, Switzerland for providing AS Bcl-XL oligonucleotides. We would also like to thank Dr John Masters, University College London for helpful advice and discussions. This project has been supported by the Cancer Research Campaign, UK and by a scholarship granted to EL Arriola from the Government of Mexico, CONACyT.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arriola, E., Rodriguez-Lopez, A., Hickman, J. et al. Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 18, 1457–1464 (1999). https://doi.org/10.1038/sj.onc.1202420
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202420
Keywords
This article is cited by
-
Evaluation and Elucidation Studies of Natural Aglycones for Anticancer Potential using Apoptosis-Related Markers: An In silico Study
Interdisciplinary Sciences: Computational Life Sciences (2018)
-
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
Oncogene (2013)
-
Melanoma: New Insights and New Therapies
Journal of Investigative Dermatology (2012)
-
Disruption of the MDM2–p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway
Cell Death & Disease (2011)
-
Inhibitory effects of transfected Bcl-XL antisense oligodeoxynucleotide to proliferation and growth in esophageal carcinoma cell line and human esophageal carcinoma xenograft of nude mice
The Chinese-German Journal of Clinical Oncology (2010)